[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
May 5, 1999

Use of Newcastle Disease Virus Vaccine (MTH-68/H) in a Patient With High-grade Glioblastoma

JAMA. 1999;281(17):1588-1589. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-17-jbk0505

To the Editor: Glioblastoma multiforme (GBM) is a highly malignant brain tumor and has a median survival time of 1 year. Newcastle disease virus (NDV) vaccine has been reported to be effective in some patients with advanced cancers who had exhausted conventional cancer treatment.1 We describe a patient with recurrent GBM who was treated with NDV vaccine and demonstrated objective tumor shrinkage and neurologic improvement.

×